The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gambarian M.G.

Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny, Moskva

Drapkina O.M.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Klinika propedevtiki vnutrennikh bolezneĭ, gastroénterologii i gepatologii

Chronic obstructive pulmonary disease and smoking: prevention principles and ways: a review

Authors:

Gambarian M.G., Drapkina O.M.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2017;20(5): 74‑82

DOI: 10.17116/profmed201720574-82

Views: 16010

Downloaded: 267

Download PDF (RU)
Contact the author
Table of contents

CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND SMOKING: PREVENTION PRINCIPLES AND WAYS: A REVIEW
CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND SMOKING: PREVENTION PRINCIPLES AND WAYS: A REVIEW

To cite this article:

Gambarian MG, Drapkina OM. Chronic obstructive pulmonary disease and smoking: prevention principles and ways: a review. Russian Journal of Preventive Medicine. 2017;20(5):74‑82. (In Russ.)
https://doi.org/10.17116/profmed201720574-82

Подписка 2025-2 (Russian Journal of Preventive Medicine)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Inte­rnet search queries on toba­cco and nico­tine consumption in 2010—2020: dyna­mics analysis. Russian Journal of Preventive Medi­cine. 2024;(5):7-11
The impact of arti­ficial inte­lligence on double reading of mammograms. Russian Journal of Preventive Medi­cine. 2024;(5):32-37
Smoking prevalence among students of medi­cal university. Russian Journal of Preventive Medi­cine. 2024;(6):29-35
Asso­ciations of smoking status with the composition of fatty acids in blood plasma in men in Novo­sibirsk («ESSE-RF3» in the Novo­sibirsk region). Russian Journal of Preventive Medi­cine. 2024;(6):36-41
Clinical and epidemiological characteristics of bronchial asthma and chro­nic obstructive pulmonary disease inci­dence in Russia before and during the COVID-19 epidemy. Russian Journal of Preventive Medi­cine. 2024;(6):42-48
Methods of cost-effectiveness evaluation of endo­vascular patent fora­men ovale closure for seco­ndary prevention of cryptogenic stroke. Russian Journal of Preventive Medi­cine. 2024;(6):105-110
Impact of meta­bolic para­meters and risk factors on surfactant proteins SP-A and SP-D in abdo­minal obesity. Russian Journal of Preventive Medi­cine. 2024;(7):60-66
Topi­cal application of hypo­tensive drugs for the prevention of intraocular pressure elevation after intravitreal inje­ctions of anti-VEGF drugs. Russian Annals of Ophthalmology. 2024;(2-2):73-79
Arti­ficial inte­lligence in dermatology: oppo­rtunities and prospects. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(3):246-252
Thoracoscopic thymectomy for myasthenia gravis and non-invasive thymoma after COVID-19 pneumonia. Piro­gov Russian Journal of Surgery. 2024;(8):26-33

Chronic obstructive pulmonary disease (COPD) is a serious global public health problem, reflecting the rising trends in morbidity and mortality from smoking-related diseases. Smoking is a major modifiable risk factor for COPD. Modern understanding of the problem suggests that this disease develops in 50% of tobacco users rather than in 15% as previously thought; that COPD can originate even in utero and in early childhood, and the understanding of the mechanisms underlying the disease is extremely important for its timely prevention. Prevention of COPD should be aimed at overcoming tobacco consumption, taking into account all other risk factors for these diseases. Current smoking cessation programs include behavioural advisory support in combination with pharmacotherapy with first-line medications, such as nicotine replacement therapy or varenicline. COPD patients need more care than healthy smokers, and smoking cessation interventions are the most cost-effective measure to reduce the rates of pulmonary function decline and morbidity and mortality from this disease.

Keywords:

chronic obstructive pulmonary disease
chronic respiratory diseases
smoking
tobacco consumption
prevention of COPD
treatment of tobacco dependence

Authors:

Gambarian M.G.

Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny, Moskva

Drapkina O.M.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Klinika propedevtiki vnutrennikh bolezneĭ, gastroénterologii i gepatologii

List of references:

  1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765-773.
  2. Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and lowincome countries. Part I. The Burden of Obstructive Lung Disease (BOLD) Initiative. Int J Tuberc Lung Dis. 2008;12:703-708.
  3. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002—2030. Ann Trop Med Parasitol. 2006; 481-499,100.
  4. Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21:14-23. https://doi.org/10.1111/resp.12660
  5. Causes of death statistics, Data from September 2012. http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Causes_of_death_statistics
  6. Global Health Observatory (GHO). http://www.who.int/gho/countries/rus/country_profiles/en/index.html
  7. 2013—2020, Global action plan for the prevention and control of noncommunicable diseases, WHO. http://www.who.int/global-coordination-mechanism/publications/global-action-plan-ncds-eng.pdf
  8. Marsh S, Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Smoking and COPD: what really are the risks? Eur Respir J. 2006;28:883-886.
  9. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet. 2006; 367:1216-1219.
  10. Global Strategy for the Diagnosis, Management, and Prevention for Chronic Obstructive Lung Disease (GOLD), revision of 2014. (In Russ.)
  11. Lundback B, Lindberg A, Lindstrom M, Rönmark E, Jonsson AC, Jönsson E, Larsson LG, Andersson S, Sandström T, Larsson K. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003;97:115-122.
  12. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015;899-909, 385.
  13. Gambaryan MG, Kalinina AM, Didkovskij NA, Oganov RG. Risk factors for Chronic Obstructive Pulmonay diseases: management of the risks, related to tobacco. Profilaktika zabolevanij i ukreplenie zdorov’ja. 2003;1:30-36. (In Russ.)
  14. Ghambarian MG, Kalinina AM, Feenstra T, Zwanikken P. COPD: can prevention be improved? Proposal for an integrated intervention strategy. Preventive Medicine. 2004;39:337-343.
  15. Gambaryan MG, Didkovskij NA, Kalinina AM, Deev AD. Risk factors for chronic obstructive pulmonary disease, interrelations of those and prognostic values. Pulmonologia. 2006;3:72-76. (In Russ.)
  16. Eisner MD, Balmes J, Katz BP, Trupin L, Yelin E, Blanc P. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health Perspect. 2005;4:7-15.
  17. Syurin SА, Nikanov АN, Rocheva II. Panichev D.V. The role of smoking in development of bronchial and lung diseases in the workers of nickel production. Medicina truda i promyshlennaya ekologia. 2007;4:44-46. (In Russ.)
  18. Gambaryan MG, Kalinina AM, Shalnova SA, Deev AD. Epidemiological features of chronic respiratory diseases in different climate-geographical regions of Russia. Pulmonologia. 2014;3:55-61. (In Russ.)
  19. Gambaryan MG. Epidemiological distinctions of chronic respiratory diseases in a number of areas of Russian Arctic with developed industry. Review. Profilakticheskaja medicina. 2014; 17(6):71-78. (In Russ.)
  20. Gambaryan MG, Kalinina AM, Shalnova SA, Smirnova MI, Deev AD. A study of the epidemological distinctions of chronic respiratory diseases in relation of the region of inhabitance in Russia. Profilakticheskaja medicina. 2015; 18(1):14-20. (In Russ.)
  21. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. International Journal of Chronic Obstructive Pulmonary Disease. 2011;6:413-421. https://doi.org/10.2147/COPD.S10770
  22. Saetta M. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:S17-S20.
  23. Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, Ciaccia A, Fabbri LM. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis. 1993;147:301-306.
  24. Rutgers SR, Postma DS ten Hacken NH, Kauffman H, van der Mark TW, Koeter G, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000;55:12-18.
  25. Agusti A, Macnee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax. 2003;58:832-834.
  26. Cosio MG. Autoimmunity, T-cells and STAT-4 in the pathogenesis of chronic obstructive pulmonary disease. Eur Respir J. 2004;24:3-5.
  27. O Senn EW, Imboden RM, Probst-Hensch NM. α1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. European Respiratory Journal. 2005 Nov;26(5):909-917. https://doi.org/10.1183/09031936.05.00021605
  28. Stoller JK, Aboussouan LS. A review of a1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012 Feb 1;185(3):246-259.
  29. van den Berge M, Vonk JM, Gosman M, et al. Clinical and infl ammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J. 2012;40:1098-1105.
  30. Tashkin DP, Altose MD, Bleecker ER, et al, for the Lung Health Study Research Group. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airfl ow limitation. Am Rev Respir Dis. 1992;145:301-310.
  31. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA, and the Lung Health Study Research Group. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:1802-1811.
  32. Li YF, Langholz B, Salam MT, Gilliland FD. Maternal and grandmaternal smoking patterns are associated with early childhood asthma. Chest. 2005;127:1232-1241.
  33. Marcon A, Cerveri I, Wjst M, et al. Can an airway challenge testpredict respiratory diseases? A population-based international study. J Allergy Clin Immunol. 2014;133:104-110.e1-4.
  34. Van Den Berge M, Meijer RJ, Kerstjens HAM, et al. PC(20) adenosine 5´-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med. 2001; 163:1546-1550.
  35. van den Berge M, Kerstjens HAM, Meijer RJ, et al. Corticosteroidinduced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway infl ammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med. 2001;164:1127-1132.
  36. Hardaker KM, Downie SR, Kermode JA, Berend N, King GG, Salome CM. Ventilation heterogeneity is associated with airway responsiveness in asthma but not COPD. Respir Physiol Neurobiol. 2013;189:106-111.
  37. Palmer LJ, Rye PJ, Gibson NA, Burton PR, Landau LI, Lesouef PN. Airway responsiveness in early infancy predicts asthma, lung function, and respiratory symptoms by school age. Am J Respir Crit Care Med. 2001; 163:37-42.
  38. Bisgaard H, Jensen SM, Bonnelykke K. Interaction between asthma and lung function growth in early life. Am J Respir Crit Care Med. 2012;185: 1183-1189.
  39. Wilson NM, Lamprill JR, Mak JC, Clarke JR, Bush A, Silverman M. Symptoms, lung function, and beta2-adrenoceptor polymorphisms in a birth cohort followed for 10 years. Pediatr Pulmonol. 2004;38:75-81.
  40. Reiss A, Wigg B, Verburgt L. Morphologic determinants of airway responsiveness in chronic smokers. Am J Respir Crit Care Med. 1996 Nov; 154(5):1444-1449.
  41. Juusela M, Pallasaho P, Rönmark E, Sarna S, Sovijärvi A, Lundbäck B. Dose-dependent association of smoking and bronchial hyperresponsiveness. European Respiratory Journal. 2013 Dec;42(6):1503-1512. https://doi.org/10.1183/09031936.00073712
  42. Eisner MD, Anthonisen N, Coultas D, et al, and the Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:693-718.
  43. Svanes C, Sunyer J, Plana E, et al. Early life origins of chronic obstructive pulmonary disease. Thorax. 2010;65:14-20.
  44. Beyer D, Mitfessel H, Gillissen A. Maternal smoking promotes chronic obstructive lung disease in the off spring as adults. Eur J Med Res. 2009; 14(suppl 4):27-31.
  45. Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure aff ects global and gene-specifi c DNA methylation. Am J Respir Crit Care Med. 2009;180:462-467.
  46. Stick SM, Burton PR, Gurrin L, Sly PD, LeSouef PN. Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants. Lancet. 1996;348:1060-1064.
  47. Doruk S, Ozyurt H, Inonu H, Erkorkmaz U, Saylan O, Seyfi kli Z. Oxidative status in the lungs associated with tobacco smoke exposure. Clin Chem Lab Med. 2011;49:2007-2012.
  48. Lodrup Carlsen KC, Jaakkola JJ, Nafstad P, Carlsen KH. In utero exposure to cigarette smoking influences lung function at birth. Eur Respir J. 1997;10:1774-1779.
  49. Janson C, Chinn S, Jarvis D, Zock JP, Toren K, Burney P, and the European Community Respiratory Health Survey. Effect of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community. Respiratory Health Survey: a cross-sectional study. Lancet. 2001;358:2103-2109.
  50. Simoni M, Baldacci S, Puntoni R, et al. Respiratory symptoms/diseases and environmental tobacco smoke (ETS) in never smoker Italian women. Respir Med. 2007;101:531-538.
  51. Yin P, Jiang CQ, Cheng KK, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet. 2007;370:751-757.
  52. Taylor DHJr, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health. 2002;92:990-996.
  53. van Schayck CP, Kaper J. Smoking and COPD: will they ever vanish into smoke? (Editorial). Primary Care Respir J. 2006;15:81-83.
  54. Xu X, Dockery DW, Ware JH, Speizer FE, Ferris BG. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am Rev Respir Dis. 1992;146:1345-1348.
  55. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri LM, Donner CF, Saetta M. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158:1277-1285.
  56. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WAJr, Enright PL, Kanner RE, O’Hara, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of. decline of FEV 1. The Lung Health Study. JAMA. 1994;272:1497-1505.
  57. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality. A randomized clinical trial. Ann Intern Med. 2005;142:233-239.
  58. Murray RP, Anthonissen NR, Connett JE, Wise RA, Lindgren PG, Greene PG, Nides MA. Effect of multiple attempts to quit smoking and relapses to smoking on pulmonary function. J Clin Epid. 1998;51:1317-1326.
  59. Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with mild chronic obstructive pulmonary disease. The Lung Health Study. Am J Med. 1999;106:406-410.
  60. Fletcher C, Peto R, Tinker C. The natural history of chronic airflow obstruction. BMJ. 1977;1:1645-1648.
  61. Xu X, Dockery DW, Ware JH, Speizer FE, Ferris BG. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am Rev Respir Dis. 1992;146:1345-1348.
  62. Wagena EJ, Knipschild P, Huibers MJH, Wouters EFM, van Schayck CP. The efficacy of bupropion and nortriptyline for smoking cessation among people who are at risk for or have chronic obstructive pulmonary disease: a randomizaed, placebo-controlled trial. Arch Int Med. 2005;165:2286-2292.
  63. Zielinszky J, Bednarek M. Early detection of COPD in a high-risk population using spirometric screening. Chest. 2001;119:731-736.
  64. Stratelis G, Mölstad S, Jakobsson P, Zetterström O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scandinavian J Primary Health Care. 2006;24:133-139.
  65. Federal’nyj zakon №15-FZ ot 23.02.13 «Ob ohrane zdorov’ja grazhdan ot vozdejstvija okruzhajushhego tabachnogo dyma i posledstvij potreblenija tabaka». b.m: Specializirovannyj pravovoj sajt Konsul’ tantPljus - www.consultant.ru. (In Russ.)
  66. Prikaz Minzdrava Rossii №683n ot 30.09.15 «Ob utverzhdenii Porjadka organizacii i osushhestvlenija profilaktiki neinfekcionnyh zabolevanij i provedenija meroprijatij po formirovaniju zdorovogo obraza zhizni v medicinskih organizacijah». (Zaregistrirovano v Minjuste Rossii 24.11.15 №39822) Specializirovannyj pravovoj sajt Konsul’tantPljus — www.consultant.ru (In Russ.)
  67. Prikaz Ministerstva zdravoohranenija i social’nogo razvitija RF №543n ot 15.05.12 «Ob utverzhdenii Polozhenija ob organizacii okazanija pervichnoj mediko-sanitarnoj pomoshhi vzroslomu naseleniju». s izmenenijami i dopolnenijami ot: 23 ijunja, 30 sentjabrja 2015 g. Specializirovannyj pravovoj sajt Konsul’tantPljus - www.consultant.ru (In Russ.)
  68. West R, Raw M, McNeill A, et al. Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development. Addiction. 2015;110:1388-1403.
  69. LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database of Systematic Reviews. 2008;Issue 4.
  70. Rose G, Colwell L, Randomised controlled trial of anti-smoking advice: final (20 year) results. Journal of Epidemiology and Community Health. 1992;46:75-77.
  71. Michie S, Hyder N, Walia A,West R. Development of a taxonomy of behaviour change techniques used in individual behavioural support for smoking cessation. Addict Behav. 2011;36:315-319.
  72. West R, Evans A, Michie S. Behavior change techniques used in group-based behavioral support by the English stop smoking services and preliminary assessment of association with short-term quit outcomes. Nicotine Tob Res. 2011;13:1316-1320.
  73. Lancaster T, Stead LF, Individual behavioural counselling for smoking cessation (review). The Cochrane Library. 2008;Issue 4.
  74. Stead LF, Lancaster T, Group behaviour therapy programmes for smoking cessation (review). The Cochrane Library. 2009;Issue 2.
  75. Ramos M, et al. Effectiveness of intensive group and individual interventions for smoking cessation in primary health care settings: a randomized trial. BMC Public Health. 2010.
  76. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2012;12CD009670.
  77. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2013;8CD002850.
  78. Gilbert H, Sutton S. Evaluating the effectiveness of proactive telephone counselling for smoking cessation in a randomized controlled trial. Addiction. 2006;101:590-598.
  79. Michie S, Free C, West R. Characterising the ‘Txt2Stop’ smoking cessation text messaging intervention in terms of behaviour change techniques. J Smoking Cessation. 2012;7:55-60.
  80. Whittaker R, McRobbie H, Bullen C, Borland R, Rodgers A, Gu Y. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev. 2012;11CD006611.
  81. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Rockville, U.S. Department of Health and Human Services. Clinical Practice Guideline. 2008.
  82. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
  83. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD000031.
  84. Tran K, Asakawa K, et al. Pharmacologic-based Strategies for Smoking Cessation: Clinical and Cost-Effectiveness Analyses, Canadian Agency for Drugs and Technologies in Health, 2010. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442619/
  85. Instrukcija po medicinskomu primeneniju preparata Champiks, odobrena Roszdravnadzorom ot 18.06.09 s izmenenijami ot 03.04.13, 02.08.13 i 05.03.14. (In Russ.)
  86. Vadasz I. The first Hungarian experiences with varenicline to support smoking cessation. Medicina Thoracalis. 2009 February 1;62:1-9.
  87. Gonzales D, Rennard SI, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation a randomized controlled trial. JAMA. 2006;296:1:47-55. https://doi.org/10.1001/jama.296.1.47
  88. Rollema H, Coe J, Chambers L, et al. Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007;28:316-325.
  89. Cahill K, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis (review). The Cochrane Collaboration and published. The Cochrane Library. 2013;Issue 5:2.
  90. Tønnesen Ph. Smoking cessation and COPD. European respiratory review. 2013 Mar;22(127):37-43. https://doi.org/10.1183/09059180.00007212
  91. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;1CD000031.
  92. Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2012;CD006103. https://doi.org/10.1002/14651858. CD006103.pub6
  93. Vinnikov D, Brimkulov N, Burjubaeva A. A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. Journal of Smoking Cessation. 2008;3(1):57-62.
  94. Bader P, McDonald PW, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a delphi panel of international experts. Tob Control. 2008;13. https://doi.org/10.1136/tc.2008.025635
  95. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139:591-599.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.